Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

36OL

Crystal Structure of KRAS WT complexed with GMPPNP

36OL の概要
エントリーDOI10.2210/pdb36ol/pdb
分子名称GTPase KRas, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, ... (5 entities in total)
機能のキーワードinhibitor, complex, small gtpase, cancer, tri-complex, signaling protein-inhibitor complex, signaling protein
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数2
化学式量合計39872.74
構造登録者
Tomlinson, A.C.A.,Knox, J.E.,Yano, J.K. (登録日: 2026-06-23, 公開日: 2026-07-01)
主引用文献Seamon, K.J.,Zhuang, Y.,Yang, Y.C.,Chakraborty, S.,Cregg, J.,Tomlinson, A.C.A.,Gould, A.,Ahler, E.,Maldonato, B.J.,Spradlin, J.N.,Pota, K.,Weller, C.,Marquez, A.,Wang, Z.,Koltun, E.S.,Knox, J.E.,Gill, A.L.,Smith, J.A.M.,Singh, M.,Jiang, J.,Wildes, D.,Holderfield, M.
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers.
Cancer Discov, 2026
Cited by
PubMed Abstract: Covalent KRAS G12C inhibitors have changed the treatment landscape for NSCLC and CRC patients, but numerous RAS-mutant cancers lack approved targeted therapies. Here we describe RMC-8839, an oral RAS(ON) G13C-selective, covalent, tri-complex inhibitor that induced tumor regressions in selected KRAS G13C-mutant xenograft models. However, one-third of KRAS G13C-mutant human cancer cell lines in vitro showed incomplete RAS pathway suppression despite near-complete KRAS G13C engagement, suggesting a role for wild-type RAS(ON). We find that codon 13-mutant RAS differs from other KRAS mutations, exhibiting decreased stability, increased nucleotide exchange, and substantial intrinsic and GAP-stimulated GTP hydrolysis, which decreases oncogenicity. Furthermore, co-occurring RAS pathway mutations leading to increased wild-type RAS activation are enriched in codon 13 mutant tumors. Consistent with a role for wild-type RAS(ON) signaling, combination of RMC-8839 with a RAS(ON) multi-selective inhibitor resulted in deeper inhibition of KRAS G13C-mutant xenograft tumor growth than either inhibitor alone.
PubMed: 42329095
DOI: 10.1158/2159-8290.CD-25-0886
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.05 Å)
構造検証レポート
Validation report summary of 36ol
検証レポート(詳細版)ダウンロードをダウンロード

255900

件を2026-07-01に公開中

PDB statisticsPDBj update infoContact PDBjnumon